CNSP
Price
$8.73
Change
-$0.00 (-0.00%)
Updated
Sep 18, 12:01 PM (EDT)
Capitalization
5.25M
PTGX
Price
$61.52
Change
+$2.30 (+3.88%)
Updated
Sep 18, 01:32 PM (EDT)
Capitalization
3.64B
48 days until earnings call
Interact to see
Advertisement

CNSP vs PTGX

Header iconCNSP vs PTGX Comparison
Open Charts CNSP vs PTGXBanner chart's image
CNS Pharmaceuticals
Price$8.73
Change-$0.00 (-0.00%)
Volume$116
Capitalization5.25M
Protagonist Therapeutics
Price$61.52
Change+$2.30 (+3.88%)
Volume$166
Capitalization3.64B
CNSP vs PTGX Comparison Chart in %
Loading...
CNSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CNSP vs. PTGX commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNSP is a Buy and PTGX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (CNSP: $8.88 vs. PTGX: $59.22)
Brand notoriety: CNSP and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CNSP: 34% vs. PTGX: 118%
Market capitalization -- CNSP: $5.25M vs. PTGX: $3.64B
CNSP [@Biotechnology] is valued at $5.25M. PTGX’s [@Biotechnology] market capitalization is $3.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CNSP’s FA Score shows that 2 FA rating(s) are green whilePTGX’s FA Score has 1 green FA rating(s).

  • CNSP’s FA Score: 2 green, 3 red.
  • PTGX’s FA Score: 1 green, 4 red.
According to our system of comparison, PTGX is a better buy in the long-term than CNSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CNSP’s TA Score shows that 5 TA indicator(s) are bullish while PTGX’s TA Score has 4 bullish TA indicator(s).

  • CNSP’s TA Score: 5 bullish, 4 bearish.
  • PTGX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CNSP is a better buy in the short-term than PTGX.

Price Growth

CNSP (@Biotechnology) experienced а +26.86% price change this week, while PTGX (@Biotechnology) price change was +2.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.40%. For the same industry, the average monthly price growth was +12.19%, and the average quarterly price growth was +39.12%.

Reported Earning Dates

PTGX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.65B) has a higher market cap than CNSP($5.25M). PTGX has higher P/E ratio than CNSP: PTGX (81.12) vs CNSP (0.00). PTGX YTD gains are higher at: 53.420 vs. CNSP (-87.708). PTGX has higher annual earnings (EBITDA): 26.8M vs. CNSP (-15.44M). PTGX has more cash in the bank: 570M vs. CNSP (12.1M). CNSP has less debt than PTGX: CNSP (122K) vs PTGX (11.3M). PTGX has higher revenues than CNSP: PTGX (209M) vs CNSP (0).
CNSPPTGXCNSP / PTGX
Capitalization5.25M3.65B0%
EBITDA-15.44M26.8M-58%
Gain YTD-87.70853.420-164%
P/E Ratio0.0081.120%
Revenue0209M-
Total Cash12.1M570M2%
Total Debt122K11.3M1%
FUNDAMENTALS RATINGS
CNSP vs PTGX: Fundamental Ratings
CNSP
PTGX
OUTLOOK RATING
1..100
280
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10048
SMR RATING
1..100
10063
PRICE GROWTH RATING
1..100
5048
P/E GROWTH RATING
1..100
63
SEASONALITY SCORE
1..100
6n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CNSP's Valuation (9) in the null industry is significantly better than the same rating for PTGX (79) in the Biotechnology industry. This means that CNSP’s stock grew significantly faster than PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (48) in the Biotechnology industry is somewhat better than the same rating for CNSP (100) in the null industry. This means that PTGX’s stock grew somewhat faster than CNSP’s over the last 12 months.

PTGX's SMR Rating (63) in the Biotechnology industry is somewhat better than the same rating for CNSP (100) in the null industry. This means that PTGX’s stock grew somewhat faster than CNSP’s over the last 12 months.

PTGX's Price Growth Rating (48) in the Biotechnology industry is in the same range as CNSP (50) in the null industry. This means that PTGX’s stock grew similarly to CNSP’s over the last 12 months.

PTGX's P/E Growth Rating (3) in the Biotechnology industry is in the same range as CNSP (6) in the null industry. This means that PTGX’s stock grew similarly to CNSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CNSPPTGX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CNSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSCKX17.37N/A
N/A
Goldman Sachs International Eq Inc C
APGYX123.57N/A
N/A
AB Large Cap Growth Advisor
USPCX31.13N/A
N/A
Union Street Partners Value C
BCREX14.86N/A
N/A
BlackRock Real Estate Securities Inv C
IRLIX44.47-0.05
-0.11%
Voya Russell Large Cap Index Port A

CNSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CNSP has been loosely correlated with PMN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CNSP jumps, then PMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CNSP
1D Price
Change %
CNSP100%
-2.84%
PMN - CNSP
51%
Loosely correlated
+7.31%
VIR - CNSP
36%
Loosely correlated
-1.23%
AAVXF - CNSP
34%
Loosely correlated
N/A
MURA - CNSP
32%
Poorly correlated
+0.48%
PTGX - CNSP
30%
Poorly correlated
+1.08%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been closely correlated with BIESF. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if PTGX jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+1.08%
BIESF - PTGX
66%
Closely correlated
N/A
TRVI - PTGX
41%
Loosely correlated
+0.13%
DNLI - PTGX
41%
Loosely correlated
-1.51%
MLYS - PTGX
39%
Loosely correlated
-0.39%
ORMP - PTGX
37%
Loosely correlated
-1.09%
More